Review
The role of interleukin 13 and the type 2 immune pathway in COVID-19: A review

https://doi.org/10.1016/j.anai.2023.03.009Get rights and content
Under a Creative Commons license
open access

Abstract

Although much has been learned about severe acute respiratory syndrome coronavirus 2 since December 2019, uneven global vaccine distribution, rapid viral spread, and variant evasion of preventative measures have led to its persistence in the population for the foreseeable future. Additional therapies are needed to support patients through their acute, immune-mediated disease process that continues to lead to considerable morbidity and mortality. Data revealing the involvement of type 2 immune pathway in acute coronavirus disease 2019 and post-recovery conditions represent a potential additional area for intervention. Herein, we review the current understanding of interleukin 13 in acute severe acute respiratory syndrome coronavirus 2 infection, the clinical outcomes associated with type 2 immune processes, and the impact of type 2 blockade on acute and long-term coronavirus disease 2019 conditions.

Cited by (0)

Disclosures: The authors have no conflicts of interest to report.

Funding: The Manning Family Foundation and NIH grants R01 AI124214, R01 AI152477 and 2R37AI026649.